Commonwealth Equity Services’s Franklin Genomic Advancements ETF HELX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-6,677
Closed -$212K – 4126
2024
Q2
$212K Sell
6,677
-365
-5% -$11.4K ﹤0.01% 3592
2024
Q1
$231K Hold
7,042
– – ﹤0.01% 3506
2023
Q4
$215K Sell
7,042
-915
-11% -$25.4K ﹤0.01% 3450
2023
Q3
$225K Buy
7,957
+38
+0.5% +$1.14K ﹤0.01% 3282
2023
Q2
$239K Sell
7,919
-792
-9% -$24K ﹤0.01% 3235
2023
Q1
$264K Sell
8,711
-324
-4% -$10K ﹤0.01% 3074
2022
Q4
$272K Buy
9,035
+188
+2% +$5.78K ﹤0.01% 2951
2022
Q3
$262K Buy
8,847
+372
+4% +$12.3K ﹤0.01% 2934
2022
Q2
$271K Sell
8,475
-2,143
-20% -$70.7K ﹤0.01% 2931
2022
Q1
$392K Sell
10,618
-4,382
-29% -$167K ﹤0.01% 2733
2021
Q4
$727K Sell
15,000
-131
-0.9% -$6.53K ﹤0.01% 2224
2021
Q3
$791K Sell
15,131
-1,191
-7% -$64.4K ﹤0.01% 2109
2021
Q2
$845K Sell
16,322
-55
-0.3% -$2.46K ﹤0.01% 2048
2021
Q1
$710K Buy
16,377
+10,279
+169% +$481K ﹤0.01% 2062
2020
Q4
$270K Buy
6,098
+178
+3% +$7.09K ﹤0.01% 2665
2020
Q3
$207K Buy
+5,920
New +$202K ﹤0.01% 2689

Other funds holding HELX

Commonwealth Equity Services's HELX Position: Q3 2024 in Review

Commonwealth Equity Services sold out of Franklin Genomic Advancements ETF (HELX) in Q3 2024, closing a stake of 6,677 shares — an estimated $212K sold.

Commonwealth Equity Services first reported a position in HELX in Q3 2020 and held it in 16 quarters. The position peaked at $845K in Q2 2021. 6 funds tracked by Wall St. Rank hold HELX as of Q3 2024.

  • Commonwealth Equity Services reported no remaining Franklin Genomic Advancements ETF position as of Q3 2024 after selling out during the quarter.
  • Commonwealth Equity Services sold 6,677 Franklin Genomic Advancements ETF shares in Q3 2024, an estimated $212K.
  • Commonwealth Equity Services first reported a position in Franklin Genomic Advancements ETF in Q3 2020 and held it in 16 quarters.
  • Commonwealth Equity Services's Franklin Genomic Advancements ETF position peaked at $845K in Q2 2021.
  • 6 funds tracked by Wall St. Rank held Franklin Genomic Advancements ETF as of Q3 2024.

Based on Commonwealth Equity Services's 13F filing for Q3 2024, filed 18 Oct 2024.